



PERMANENT MISSION OF TURKEY  
TO THE UNITED NATIONS  
GENEVA

2016/62441669-BMCO DT/10770992

The Permanent Mission of the Republic of Turkey to the United Nations Office at Geneva and other International Organisations in Switzerland presents its compliments to the Implementation Support Unit of the "Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological and Toxin Weapons and on Their Destruction" (BWC) and has the honour to enclose herewith the annual declaration of confidence building measures (CBMs) of the Republic of Turkey relating to the BWC covering the period of 1 January 2015- 31 December 2015.

The Permanent Mission of the Republic of Turkey to the United Nations Office at Geneva and other International Organisations in Switzerland avails itself of this opportunity to renew to the Implementation Support Unit of the BWC the assurances of its highest consideration.

Geneva, 12 April 2016



Encl:1

BWC Implementation Support Unit  
United Nations Office for Disarmament  
Affairs (Geneva Branch)  
Palais des Nations / CH-1211 Geneva

## Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

### Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input checked="" type="checkbox"/>	2014
A, part 2 (i)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
A, part 2 (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>	2014
F	<input type="checkbox"/>	<input checked="" type="checkbox"/>	2014
G	<input type="checkbox"/>	<input checked="" type="checkbox"/>	2014

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: **8 April 2016**

State Party to the Convention: **Republic of Turkey**

Date of ratification/accession to the Convention: **1974**

National point of contact: **F. Aykut Renda, Head of Department, Department of Arms Control and Disarmament, Ministry of Foreign Affairs, Ankara-Turkey**

E-mail: **aykut.renda@mfa.gov.tr**

## Confidence-Building Measure "A"

### Part 1 Exchange of data on research centres and laboratories

At the Third Review Conference it was agreed that States Parties continue to implement the following:

"Exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a high individual and community risk or specialize in permitted biological activities directly related to the Convention."

#### Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

Data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the latest edition of the WHO<sup>1</sup> Laboratory Biosafety Manual and/or OIE<sup>2</sup> Terrestrial Manual or other equivalent guidelines adopted by relevant international organisations, such as those designated as biosafety level 4 (BL4, BSL4 or P4) or equivalent standards.

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

#### Form A, part 1 (i)

##### *Exchange of data on research centres and laboratories<sup>3</sup>*

1. Name(s) of facility<sup>4</sup> \_\_\_\_\_
2. Responsible public or private  
organization or company \_\_\_\_\_
3. Location and postal address \_\_\_\_\_
  
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

---

<sup>1</sup> World Health Organization

<sup>2</sup> World Organization for Animal Health

<sup>3</sup> The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

<sup>4</sup> For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

## **Part 2 Exchange of information on national biological defence research and development programmes**

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

- (1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;
- (2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;
- (3) The organizational structure of the programme and its reporting relationships; and
- (4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;
  - (a) location;
  - (b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;
  - (c) the total number of staff employed, including those contracted full time for more than six months;
  - (d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;
  - (e) a list of the scientific disciplines of the scientific/engineering staff;
  - (f) the source and funding levels in the following three areas: research, development, and test and evaluation; and
  - (g) the policy regarding publication and a list of publicly-available papers and reports.

### **Form A, part 2 (i)**

#### **National biological defence research and development programmes Declaration**

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

BL2 \_\_\_\_\_ (sqM)  
BL3 \_\_\_\_\_ (sqM)  
BL4 \_\_\_\_\_ (sqM)  
Total laboratory floor area \_\_\_\_\_ (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel \_\_\_\_\_

(ii) Division of personnel:

Military \_\_\_\_\_

Civilian \_\_\_\_\_

(iii) Division of personnel by category:

Scientists \_\_\_\_\_

Engineers \_\_\_\_\_

Technicians \_\_\_\_\_

Administrative and support staff \_\_\_\_\_

(iv) List the scientific disciplines represented in the scientific/engineering staff.

(v) Are contractor staff working in the facility? If so, provide an approximate number.

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

(vii) What are the funding levels for the following programme areas:

Research \_\_\_\_\_

Development \_\_\_\_\_

Test and evaluation \_\_\_\_\_

(viii) Briefly describe the publication policy of the facility:

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

## **Confidence-Building Measure "B"**

### **Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins**

At the Third Review Conference it was agreed that States Parties continue to implement the following:

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins, and on all such events that seem to deviate from the normal pattern as regards type, development, place, or time of occurrence. The information provided on events that deviate from the norm will include, as soon as it is available, data on the type of disease, approximate area affected, and number of cases.

The Seventh Review Conference agreed the following:

No universal standards exist for what might constitute a deviation from the normal pattern.

#### **Modalities**

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

1. Exchange of data on outbreaks that seem to deviate from the normal pattern is considered particularly important in the following cases:

- When the cause of the outbreak cannot be readily determined or the causative agent<sup>10</sup> is difficult to diagnose,
- When the disease may be caused by organisms which meet the criteria for risk groups III or IV, according to the classification in the latest edition of the WHO Laboratory Biosafety Manual,
- When the causative agent is exotic to a given geographical region,
- When the disease follows an unusual pattern of development,
- When the disease occurs in the vicinity of research centres and laboratories subject to exchange of data under item A,
- When suspicions arise of the possible occurrence of a new disease.

2. In order to enhance confidence, an initial report of an outbreak of an infectious disease or a similar occurrence that seems to deviate from the normal pattern should be given promptly after cognizance of the outbreak and should be followed up by annual reports. To enable States Parties to follow a standardized procedure, the Conference has agreed that Form B should be used, to the extent information is known and/or applicable, for the exchange of annual information.

3. The declaration of electronic links to national websites or to websites of international, regional or other organizations which provide information on disease outbreaks (notably outbreaks of infectious diseases and similar occurrences caused by toxins that seem to deviate from the normal pattern) may also satisfy the declaration requirement under Form B.

---

<sup>10</sup> It is understood that this may include organisms made pathogenic by molecular biology techniques, such as genetic engineering.

## Form B

### Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern<sup>11</sup>

1. Time of cognizance of the outbreak \_\_\_\_\_
2. Location and approximate area affected \_\_\_\_\_
3. Type of disease/intoxication \_\_\_\_\_
4. Suspected source of disease/intoxication \_\_\_\_\_
5. Possible causative agent(s) \_\_\_\_\_
6. Main characteristics of systems \_\_\_\_\_
7. Detailed symptoms, when applicable  
- respiratory \_\_\_\_\_  
- circulatory \_\_\_\_\_  
- neurological/behavioural \_\_\_\_\_  
- intestinal \_\_\_\_\_  
- dermatological \_\_\_\_\_  
- nephrological \_\_\_\_\_  
- other \_\_\_\_\_
8. Deviation(s) from the normal pattern as regards  
- type \_\_\_\_\_  
- development \_\_\_\_\_  
- place of occurrence \_\_\_\_\_  
- time of occurrence \_\_\_\_\_  
- symptoms \_\_\_\_\_  
- virulence pattern \_\_\_\_\_  
- drug resistance pattern \_\_\_\_\_  
- agent(s) difficult to diagnose \_\_\_\_\_  
- presence of unusual vectors \_\_\_\_\_  
- other \_\_\_\_\_
9. Approximate number of primary cases \_\_\_\_\_
10. Approximate number of total cases \_\_\_\_\_
11. Number of deaths \_\_\_\_\_
12. Development of the outbreak \_\_\_\_\_
13. Measures taken \_\_\_\_\_

---

<sup>11</sup> See paragraph 2 of the chapeau to Confidence-Building Measure B.

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

## Form E

### Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures <sup>12</sup>	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	Yes	Yes	Yes	No
(b) Exports of micro-organisms <sup>13</sup> and toxins	Yes	Yes	Yes	No
(c) Imports of micro-organisms <sup>11</sup> and toxins	Yes	Yes	Yes	No
(d) Biosafety <sup>14</sup> and biosecurity <sup>15</sup>	Yes	Yes	Yes	No

---

<sup>12</sup> Including guidelines.

<sup>13</sup> Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

<sup>14</sup> In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

<sup>15</sup> In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.



## Confidence-Building Measure "G"

### Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

### Form G

#### Declaration of vaccine production facilities (veterinary use)

##### Facility No: 1

1. Name of facility :  
**Ministry of Food Agriculture and Livestock- Foot and Mouth Disease Institute**
2. Location (mailing address):  
**Eskisehir road 7.km 06044 Söğütözü/ANKARA**
3. General description of the types of diseases covered :  
**Manufacturer of Foot and Mouth Disease Vaccine**

##### Facility No: 2

1. Name of facility :  
**Ministry of Food Agriculture and Livestock - Veterinary Control Central Research Institute**
2. Location (mailing address) :  
**Ahmet Sefik Kolaylı Sokak No: 23, 06020 Etlik/ANKARA**
3. General description of the types of diseases covered :  
**Manufacturer of**
  - **Bacillus anthracis vaccine**
  - **Blue tongue vaccine**
  - **Peste Des Petits Ruminants (PPR) vaccine**

##### Facility No: 3

1. Name of facility :  
**Ministry of Food Agriculture and Livestock - Veterinary Control Institute**
2. Location (mailing address) :  
**Batı Mahallesi, Ankara Cad. No:1, 34890 Pendik/ISTANBUL**
3. General description of the types of diseases covered :  
**Manufacturer of**
  - **Brucellosis vaccines**
  - **Clostridial- vaccines**
  - **Theileriosis vaccine**
  - **Sheep-goat Pox vaccine**
  - **Ovine Ecthyma vaccine**
  - **Contagious caprine pleuropneumonia vaccine**
  - **Mycoplasma agalactiae vaccine**
  - **E. coli vaccine**